News | July 15, 2011

Canadian Researchers Look at ICD Survival Rates in Post-Heart Attack Patients

July 15, 2011 — Canada is spearheading an international study to determine if an implantable cardioverter defibrillator (ICD) can prevent death from serious heart rhythm problems in patients who have survived a heart attack. Heart disease is a leading cause of death in Canada and the fastest growing disease worldwide.

Derek Exner, M.D., of the Libin Cardiovascular Institute of Alberta at the Faculty of Medicine of the University of Calgary, leads the study, which is based on his past research (REFINE Study). Exner and colleagues developed a method to identify patients at high risk of serious heart rhythm problems after a heart attack. The institute will be the clinical coordinating centre for the study and will gather patient data from 16 sites in Canada, the United States and Europe during an initial, two-year pilot phase.

The Alberta government, Western Economic Diversification Canada, Medtronic Inc., GE Healthcare, the University of Calgary and other partners are providing $16.8 million to support the pilot phase of the project. The study may eventually grow to include 75 sites worldwide with a total investment of more than $40 million. 

 “Sudden death is a major cause of death in Canada and around the world. Research to identify those at risk and methods to prevent death from heart rhythm problems are vital. This study may change how we manage patients after a heart attack and has the potential to save thousands of lives each and every year. It is an honor to be leading such an important study,” said Exner, a heart rhythm specialist, professor in the departments of cardiac science, medicine and community health sciences at the Faculty of Medicine, and the Canada research chair in cardiovascular clinical trials.

Support from Alberta and Canada is through the Western Economic Partnership Agreement, a joint program to enhance diversification of the Alberta economy through shared investments in technology commercialization, business productivity and competitiveness, trade and investment, and value added processing.

For more information: www.libin.ucalgary.ca


Related Content

News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
Subscribe Now